NCT04260022 2025-11-05Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLAscentage Pharma Group Inc.Phase 1 Recruiting242 enrolled
NCT03595917 2025-11-04ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLDana-Farber Cancer InstitutePhase 1 Recruiting40 enrolled